我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

阿托伐他汀对不稳定型心绞痛患者PCI术后 心肌损伤及炎症反应的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第6期
页码:
720-721731
栏目:
临床研究
出版日期:
2008-12-25

文章信息/Info

Title:
Effect of atorvastatin on myocardial injure and inflammatory reaction from PCI in patients with unstable angina pectoris
作者:
刘丽珍; 郭文怡
第四军医大学西京医院心内科,陕西 西安 710032
Author(s):
LIU Lizhen;  GUO Wenyi
Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China
关键词:
冠状动脉; 介入治疗; 心肌损伤; 炎症反应; 阿托伐他汀
Keywords:
coronary artery;  percutaneous coronary intervention;  myocardial injury;  inflammatory reaction;  atorvastatin
分类号:
R514.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨阿托伐他汀常规剂量治疗对不稳定型心绞痛(UAP)患者经皮冠状动脉介入术(PCI)后,心肌损伤的标记物血清肌酸磷酸激酶同功酶（CK-MB）、血浆肌钙蛋白Ⅰ（cTnI）及炎症反应标志物超敏C反应蛋白(hs-CRP)的变化。方法 根据UAP患者PCI术前4周是否持续服用阿托伐他汀20 mg/d分为试药组和对照组,于术前和术后8 h、24 h抽取肘静脉血检测血浆CK-MB、cTnI和hs-CRP。结果 PCI术后两组心肌损伤及炎症反应的标记物均有不同程度升高,但试药组CK-MB、cTnI、hs-CRP水平显著低于对照组（均P<0.01）。结论 UAP患者在PCI术前4周持续口服阿托伐他汀20 mg/d能明显减少PCI术对UAP患者造成的心肌损伤及炎症反应。
Abstract:
AIM To study the effect of atorvastatin on myocardial injure and inflammatory reaction from percutaneous coronary intervention（PCI）in patients with unstable angina pectoris. The markers of myocardial injure are CK-MB and cardiac troponin (cTnI). The marker of inflammatory reaction is highsensitivity Creactive protein (hs-CRP). METHODS The two treatment groups received atorvastatin 20 mg daily or nonatorvastatin 4 successive weeks before PCI, CK-MB, cTnI and hs-CRP of the blood from elbow vein were monitored before and 8 and 24 hours after the procedure of PCI. RESULTS The markers of two groups were elevated after PCI, however, the ascended values of CK-MB, cTnI and hs-CRP in the atrovastatin treatment group were significantly lower than those of the compared group（P<0.01）. CONCLUSION Administering 20 mg atorvastatin daily in 4 successive weeks before PCI can significantly reduce the myocardial injury and inflammatory reaction.

参考文献/References

［1］ 于安忠,姚卫东,李继福,等. 冠状动脉介入治疗致心肌微损伤的研究进展［J］. 中国综合临床, 2004, 20(12):1147-1148.

［2］ Klugherz BD, Meneveau NF, Kolansky DM, et al. Predictors of clinical outcome following percutaneous intervention for instent restenosis［J］. Am J Cardiol, 2000, 85(12):1427-1431.

［3］ Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline Creactive protein among established markers of risk in percutaneous coronary intervention［J］. Circulation, 2001, 104(9):992-997.

［4］ Waters DD, Azar RR. Should intensive cholesterol lowing play a role in the management of acute coronary syndrome［J］. Am J Cardiol, 2000, 86(8B):35J-42J.

［5］ 莫云秋,黄洁,卫智权,等. 阿托伐他汀对不稳定型心绞痛患者IL18和超敏CRP的影响［J］. 心脏杂志, 2006, 18(5):556-558.

［6］ Kornowski R, Hong MK, Tio FO, et al. Instent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia［J］. J Am Coll Cardiol, 1998, 31（1）:224-230.

［7］ Azar RR, McKay RG, Kiernan FJ, et al. Coronary angioplasty induces a systemic inflammatory response［J］. Am J Cardiol, 1997, 80(11):1476-1480.

［8］ Grewe PH, Deneke T, Machraoui A, et al. Acute and chronic tissue response to coronary stent impantation: pathologic findings in human specimen［J］. J Am Coll Cardiol, 2000, 35(1):157-163.

［9］ 吴奇志,翁南星,兰启防,等. 阿托伐他汀钙对原发性高胆固醇血症患者血管内皮细胞依赖性舒张功能的影响［J］. 心脏杂志, 2002, 14(6):494-496.

［10］拓步雄,李慧,李晓苗. 阿托伐他汀降脂作用与血管内皮功能关系的研究［J］. 中华老年心脑血管病杂志, 2002, 4(6):377.

备注/Memo

备注/Memo:
收稿日期：2008-06-05.通讯作者：郭文怡，主任医师，主要从事冠心病研究和治疗 Email:guowenyi@tom.com 作者简介：刘丽珍，主治医师,硕士生Email:zhljingyu@163.com
更新日期/Last Update: 2009-03-24